stockrow
Friday 6 November 2026
Export UFPT’s income statement to Excel — free account
UFP Technologies, Inc.
UFPT Healthcare Medical Devices
UFP Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $602.8 million, up 19.5% from fiscal 2024.
- Revenue
- +11.6%
- EPS
- +25.6%
- Free cash flow
- −35.8%
- Total debt
- −40.2%
Quarter to September 2026, against a year earlier
302.33
2.51
+0.84%
Follow UFPT
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
29.98 | 28.33 | 21.75 | 25.03 |
+8 more quarters Free account |
P/S ratio |
3.54 | 3.25 | 2.46 | 2.84 | |
P/FCF ratio |
37.38 | 33.37 | 21.49 | 21.65 | |
P/Operating CF |
147.27 | 131.44 | 466.54 | 101.59 | |
P/B ratio |
4.97 | 4.44 | 3.41 | 4.04 | |
Price to Tangible BV |
18.05 | 15.70 | 14.32 | 19.98 | |
EV/Sales |
3.66 | 3.44 | 2.67 | 3.05 | |
EV/EBITDA |
20.47 | 18.75 | 14.52 | 16.50 | |
EV/Operating CF |
33.17 | 30.38 | 20.00 | 20.02 | |
EV/FCF |
38.61 | 35.36 | 23.38 | 23.28 | |
Quick Ratio |
1.52 | 1.61 | 1.59 | 1.45 | |
Current Ratio |
2.98 | 3.00 | 2.91 | 2.69 | |
Net Debt/EBITDA |
0.00 | 3.71 | 4.64 | 4.89 | |
Debt/Assets |
14.06% | 19.30% | 22.39% | 22.81% | |
Debt/Equity |
0.20 | 0.28 | 0.34 | 0.35 | |
Asset Turnover |
0.97 | 0.96 | 0.92 | 0.94 | |
Operating CF/Net income |
0.00 | 0.75 | 0.18 | 0.96 | |
Capex/Depreciation |
— | (0.23) | (0.34) | (0.78) | |
Interest Coverage |
18.50 | 16.42 | 13.45 | 11.14 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
13.43% | 13.08% | 13.63% | 14.08% | |
Intangible Assets out of Total Assets |
0.49 | 0.49 | 0.50 | 0.52 | |
Share Based Compensation of Revenue |
0.00% | 1.85% | 1.77% | 1.61% | |
Graham Net Nets |
0.01 | 0.01 | (0.01) | (0.02) | |
Graham Number |
0.00 | 112.17 | 106.69 | 104.78 | |
Earnings Yield |
3.34% | 3.53% | 4.60% | 3.99% | |
Free Cash Flow Yield |
2.67% | 3.00% | 4.65% | 4.62% | |
Revenue per Share |
22.26 | 22.48 | 19.97 | 19.33 | |
Operating CF per Share |
0.00 | 2.02 | 0.42 | 2.19 | |
Capex per Share |
0.00 | (0.15) | (0.22) | (0.50) | |
Free Cash Flow per Share |
0.00 | 1.87 | 0.20 | 1.69 | |
Cash per Share |
2.66 | 1.17 | 2.59 | 2.63 | |
Shareholders Equity per Share |
62.71 | 59.74 | 56.84 | 55.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
62.71 | 59.74 | 56.84 | 55.01 | |
Free Cash Flow |
— | 14.46 | 1.52 | 12.98 | |
Working Capital |
153.28 | 156.59 | 147.09 | 126.14 | |
Capital Expenditures |
— | (1.15) | (1.69) | (3.86) | |
Net Current Asset Value |
33.72 | 15.41 | (11.70) | (30.20) | |
EV/EBIT |
23.61 | 22.57 | 17.56 | 19.93 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.03 | |
Price to Operating Income |
22.86 | 21.30 | 16.15 | 18.53 | |
| Other line items | |||||
Average Receivables |
92.07 | 102.00 | 99.74 | 88.94 | |
Average Payables |
27.97 | 27.81 | 29.07 | 24.28 | |
Average Inventory |
92.15 | 92.65 | 91.91 | 87.20 | |
Average Assets |
667.73 | 658.28 | 658.66 | 642.04 | |
Average Common Equity |
— | 423.96 | 399.77 | 383.32 |
Columns are period end dates · fundamentals updated 5 Nov 2026